2025 FDA Medication Labelling 
PharmExec
AUGUST 1, 2025
Author(s): Nicholas Jacobus Key Takeaways Vizz, an aceclidine-based eye drop, is FDA-approved for presbyopia, enhancing near vision without myopic shifts. SHOW MORE LENZ Therapeutics celebrates FDA approval of Vizz, the first aceclidine eye drop for presbyopia. I want to thank each of them for their role in getting Vizz FDA approved.”
PharmExec
AUGUST 1, 2025
New labels will include study summaries, improved dosage warnings, and information on overdose reversal agents to enhance patient and healthcare professional awareness. The FDA mandates randomized clinical trials to assess long-term opioid use benefits and risks, ensuring timely and efficient completion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
AUGUST 4, 2025
The FDA will now require additional safety label changes to all opioid medications, including the risks associated with long-term use. The FDA will now require additional safety label changes to all opioid medications, including the risks associated with long-term use.
OctariusRx
MAY 27, 2025
Our 2025 Medication Calculations quiz is now available. Are you an expert at performing medication calculations or do you need practice? Nursing medication calculations are a critical component of patient safety. Very few people enjoy medication calculations, but our patients rely on us to do them well every time.
PharmExec
AUGUST 1, 2025
Related Videos Related Content Advertisement August 1st 2025 FDA Mandates Safety Alterations to Opioid Pain Medication Labels Nicholas Jacobus FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain management.
PharmExec
AUGUST 6, 2025
August 5, 2025. Sources Trump says pharma tariffs could eventually reach up to 250%. link] Newsletter Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers. Subscribe Now!
PharmExec
AUGUST 6, 2025
The announcement coincides with leadership changes and controversies at HHS, including the resignation of FDA CBER Head Vinay Prasad amidst political pressure. In late July, FDA CBER Head Vinay Prasad announced he was stepping down from the role. August 5, 2025. August 5, 2025.
Expert insights. Personalized for you.
Let's personalize your content